Ashland agrees to obtain ISP Ashland Inc get.

Ashland agrees to obtain ISP Ashland Inc. and International Specialty Items Inc. today announced that Ashland has agreed to acquire privately owned ISP, a worldwide specialty chemical manufacturer of innovative functional systems and ingredients get . Under the terms of the stock purchase agreement, Ashland can pay approximately $3.2 billion for the continuing business in an all-cash transaction. At closing, ISP’s advanced item portfolio will expand Ashland’s position in high-growth marketplaces such as personal treatment, pharmaceutical and energy. For the 12 a few months ended March 31, 2011, ISP generated product sales of approximately $1.6 billion and earnings before interest, taxes, depreciation and amortization of around $360 million.

norepinephrine receptors

Ascend Biopharmaceuticals reviews favourable results from TG1042 Stage 2 study for CBCL treatment Ascend Biopharmaceuticals, a Melbourne-based immunotherapy firm, has today announced the publication of a report utilising TG1042 for the treatment of Cutaneous B-Cell Lymphoma , in the journal PLOS One particular. Ascend Biopharmaceuticals entered into a special world-wide license contract with Transgene in July of 2013 to build up TG1042 as an immunotherapeutic injection for multiple cancers including Cutaneous B-Cell Lymphoma, CBCL . Ascend plans to sponsor and commence clinical research with TG1042 in Basal Cell Carcinoma later in 2014. Related StoriesLiposomal sizing and the Coulter basic principle: an interview with Professor Melvin E. An interview with Professor Lesley JonesViewRay obtains Korean regulatory acceptance for MRI-guided radiation therapy system The report information an open label, multi-centre trial conducted by Transgene involving 13 CBCL sufferers injected directly with TG1042 into their cancers.